Active, not recruitingPhase 2NCT04179032
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GlaxoSmithKline
- Principal Investigator
- GSK Clinical TrialsGlaxoSmithKline
- Intervention
- Belimumab(combination_product)
- Enrollment
- 25 enrolled
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2019 – 2027
Study locations (11)
- GSK Investigational Site, Cincinnati, Ohio, United States
- GSK Investigational Site, Rosario, Argentina
- GSK Investigational Site, Berlin, Germany
- GSK Investigational Site, Saint Augustin, Germany
- GSK Investigational Site, Kagoshima, Japan
- GSK Investigational Site, Kanagawa, Japan
- GSK Investigational Site, San Luis Potosí City, Mexico
- GSK Investigational Site, Rotterdam, Netherlands
- GSK Investigational Site, Barcelona, Spain
- GSK Investigational Site, Madrid, Spain
- GSK Investigational Site, Valencia, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04179032 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGPHASE2NCT05538208The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) StudyChildren's Hospital Medical Center, Cincinnati
- RECRUITINGPHASE3NCT05835310An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric ParticipantsAstraZeneca
- RECRUITINGNANCT06586710Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLEMeyer Children's Hospital IRCCS
- RECRUITINGPHASE2NCT05039619A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsHoffmann-La Roche